Clinical Research by Disease

The Department of Radiation Oncology enrolls as many as 80 new patients each year in clinical trials. Faculty members hold leadership positions in the Radiation Therapy Oncology Group (RTOG), which develops and oversees all national radiation oncology trials funded by the National Cancer Institute.

See current clinical trial information below or contact the Clinical Research office at 214-648-1892


A prospective, multicenter trial of NovoTTF-100A together with temozolomide compared to temozolomide alone in patients with newly diagnosed GBM

Interstitial radioactive iodine implants for the treatment of pan-invasive pituitary macroadenomas
Phase II trial of hippocampal-avoiding whole brain irradiation with simultaneous integrated boost for treatment of brain metastases

Phase III study of radiation therapy with or without Temozolomide for symptomatic or progressive low-grade gliomas


Phase I study of CyberKnife® partial breast irradiation (PBI) for early stage breast cancer

Phase II trial of ixabepilone and stereotactic body radiation therapy (SBRT) for patients with metastatic breast cancer


Phosphatidylserine-targeting antibody bavituximab in combination with capecitabine and radiation therapy for the treatment of stage II and III rectal adenocarcinoma


Phase II trial of stereotactic ablative body radiation therapy (SABR) for patients with primary renal cancer (RCC)

Phase II trial of high-dose IL-2 and stereotactic ablative body radiation (SABR) for patients with metastatic clear cell renal cell cancer (mRCC)

Phase II trial of sipuleucel-T and stereotactic ablative body radiation (SABR) for patients with metastatic castrate-resistant prostate cancer (mCRPC)

Phase III prospective randomized trial of dose-escalated radiotherapy with or without short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer
RTOG 0815 

Phase III trial of short-term androgen deprivation with pelvic lymph node or prostate bed only radiotherapy (SPPORT) in prostate cancer patients with a rising PSA after radical prostatectomy
RTOG 0534 

Phase III trial of dose-escalated radiation therapy and standard androgen deprivation therapy (ADT) with a GnRH agonist vs. dose escalated radiation therapy and enhanced ADT with a GnRH agonist and TAK-700 for men with high-risk prostate cancer
RTOG 1115 


Phase II study for image-guided hypofractionated radiation boost therapy for definitive treatment of locally advanced cervical cancer

A randomized phase III study of standard vs. IMRT pelvic radiation for postoperative treatment of endometrial and cervical cancer (TIME-C)
RTOG 1203 

Head and Neck

Phase 1 CyberKnife accelerated hemilarynx stereotactic radiotherapy study for early-stage glottic larynx cancer

Randomized phase II/III trial of surgery and postoperative radiation delivered with concurrent cisplatin versus docetaxel versus docetaxel and cetuximab for high-risk squamous cell cancer of the head and neck
RTOG 1216 

Phase II randomized, double blind, placebo-controlled study of lapatinib (Tykerb®) for non-HPV locally advanced head and neck cancer with concurrent chemoradiation
RTOG 3501 

Phase III study of postoperative radiation therapy (IMRT) /- Cetuximab for locally-advanced resected head and neck cancer
RTOG 0920

Randomized Phase II study of adjuvant concurrent radiation and chemotherapy versus radiation alone in resected high-risk malignant salivary gland tumors
RTOG 1008

Lung (Thoracic)

Small Cell Lung Cancer

Phase III comparison of thoracic radiotherapy regimes with Cisplatin and Etoposide in limited small cell lung cancer
CALGB 30610/RTOG 0538

Randomized Phase II study comparing prophylactic cranial irradiation alone to prophylactic cranial Irradiation and consolidative extracranial Irradiation for extensive disease small cell lung cancer (ED-SCLC)
RTOG 0937

Non-Small Cell Lung Cancer

Randomized Phase II study of preoperative chemoradiotherapy +/- Panitumumab followed by consolidation chemotherapy in potentially operable locally advanced (Stage IIIA, N2+) non-small cell lung cancer
RTOG 839

Maintenance chemotherapy versus consolidative stereotactic body radiation therapy (SBRT) plus maintenance chemotherapy for stage IV non-small cell lung cancer (NSCLC): a randomized phase II trial

A randomized phase II study of individualized combined modality therapy for stage III non-small cell lung cancer (NSCLC)
RTOG 1306

A randomized phase I/II study of nab-paclitaxel, or paclitaxel, plus carboplatin with concurrent radiation therapy followed by consolidation in patients with favorable prognosis inoperable stage IIIA/B NSCLC

Phase III randomized study of standard versus accelerated hypofractionated image-guided radiation therapy (IGRT) in patients with stage II-III non-small cell lung cancer and poor performance status


Phase II study of stereotactic body radiation therapy and vertebroplasty for localized spine metastasis

Phase II/III study of Image-guided radiosurgery/SBRT for localized spine metastasis
RTOG 0631

For more information, please contact Clinical Research Manager Jean Wu at 214-633-1753 or